AMVUTTRA Gets Priority Nod for Rare Pediatric Conditions via Voucher
Published Date: 4/21/2025
Notice
Summary
The FDA just gave the green light to AMVUTTRA (vutrisiran) for a rare kid’s disease, using a special priority review voucher to speed things up. This means faster access to important medicine for families and shows the FDA’s commitment to helping rare pediatric conditions. The approval happened on March 20, 2025, marking a big win for patients and drug developers alike.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Approves AMVUTTRA for Rare Pediatric Disease
If you are a parent or guardian of a child with a rare pediatric disease, the FDA approved AMVUTTRA (vutrisiran) on March 20, 2025. The approval (Supplement-06) redeemed a Rare Pediatric Disease Priority Review Voucher, which the notice says was used for this product's review.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-06784, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; TREMFYA (guselkumab)
The FDA just gave the green light to TREMFYA (guselkumab) for a rare pediatric disease, using a special priority review voucher. This means faster approval for treatments that kids with rare diseases really need. The approval happened on March 20, 2025, helping patients get access sooner and encouraging companies to develop more rare disease medicines.
Next: 2025-06786, Action Levels for Lead in Processed Food Intended for Babies and Young Children; Guidance for Industry; Availability; Correction
The FDA fixed a mistake in a January 2025 notice about lead limits in baby and toddler foods. This guidance helps food makers keep lead levels safe for little ones. No new rules or costs—just a clearer message to protect kids.